Chemours Co

Liquidity and Capital Allocation As of June 30, 2025, consolidated gross debt was $4.2 billion.

SEC original ↗Chemours Co — Earnings release (8-K exhibit)EX-99Aug 5, 2025

Debt, net of $502 million in unrestricted cash and cash equivalents, was $3.7 billion, resulting in a net leverage ratio of approximately 4.7x on a trailing twelve-month Adjusted EBITDA basis.

SEC original ↗Chemours Co — Earnings release (8-K exhibit)EX-99Aug 5, 2025

Total liquidity was $1.5 billion, comprised of $502 million in unrestricted cash and cash equivalents and $954 million of revolving credit facility capacity, net of outstanding letters of credit.

SEC original ↗Chemours Co — Earnings release (8-K exhibit)EX-99Aug 5, 2025

Capital expenditures for the second quarter of 2025 amounted to $43 million, a decrease in spend compared to $73 million in the prior-year quarter, driven by lower capital expenditures in APM and TSS.

SEC original ↗Chemours Co — Earnings release (8-K exhibit)EX-99Aug 5, 2025

During the quarter, the Company paid $13 million in dividends to shareholders.

SEC original ↗Chemours Co — Earnings release (8-K exhibit)EX-99Aug 5, 2025

Effective August 5, 2025, the Company’s Board of Directors declared a quarterly cash dividend of $0.0875 per share on the Company’s common stock for the third quarter of 2025.

SEC original ↗Chemours Co — Earnings release (8-K exhibit)EX-99Aug 5, 2025

“We also remain equally focused on the other key pillars in our strategy with an emphasis on Operational Excellence, considering recent operational headwinds as we work to drive an improved operating model to reduce business disruptions going forward.

SEC original ↗Chemours Co — Earnings release (8-K exhibit)EX-99Aug 5, 2025

5 In January 2025, under the Portfolio Management pillar of Pathway to Thrive, as a part of a broader strategic review of our APM European asset footprint, APM management approved a restructuring program to exit its SPS Capstone business.

SEC original ↗Chemours Co — Earnings release (8-K exhibit)EX-99Aug 5, 2025

These forward-looking statements may address, among other things, guidance on Company and segment performance for the second quarter of 2025, the full year 2025 and the Company’s refreshed corporate strategy.

SEC original ↗Chemours Co — Earnings release (8-K exhibit)EX-99Aug 5, 2025

EXHIBIT 99.1 CONTACTS: INVESTORS Brandon Ontjes Vice President, Head of Strategy & Investor Relations +1.302.773.3309 investor@chemours.

SEC original ↗Chemours Co — Earnings release (8-K exhibit)EX-99Aug 5, 2025

4 In January 2025, under the Portfolio Management pillar of Pathway to Thrive, as a part of a broader strategic review of our APM European asset footprint, APM management approved a restructuring program to exit its SPS Capstone business.

SEC original ↗Chemours Co — Presentation / slide deck (8-K exhibit)EX-99Aug 5, 2025

“We also remain equally focused on the other key pillars in our strategy with an emphasis on Operational Excellence, considering recent operational headwinds as we work to drive an improved operating model to reduce business disruptions going forward.

SEC original ↗Chemours Co — Earnings release (8-K exhibit)EX-99Aug 5, 2025

2 Non-GAAP measures, including Adjusted Net Income, Adjusted EPS and Adjusted EBITDA referred to throughout, principally exclude the impact of recent litigation settlements for legacy environmental matters and associated fees, in addition to other unallocated items – please refer to the attached Reconciliation of GAAP Financial Measures to Non-GAAP Financial Measures (Unaudited)”.

SEC original ↗Chemours Co — Earnings release (8-K exhibit)EX-99Aug 5, 2025

EXHIBIT 99.1 Second quarter 2025 Net Loss attributable to Chemours was $381 million, or $2.54 per diluted share, compared to Net Income attributable to Chemours of $60 million, or $0.39 per diluted share in the prior-year quarter, primarily driven by litigation-related charges pertaining to the announced settlement with the State of New Jersey 4 and related tax impacts.

SEC original ↗Chemours Co — Earnings release (8-K exhibit)EX-99Aug 5, 2025

4 $257 million of litigation-related charges pertaining to the announced settlement with the state of New Jersey were recorded within Selling, general, and administrative expense for the second quarter of 2025.

SEC original ↗Chemours Co — Earnings release (8-K exhibit)EX-99Aug 5, 2025

Through our three businesses – Thermal & Specialized Solutions, Titanium Technologies, and Advanced Performance Materials – we deliver application expertise and chemistry-based innovations that solve customers’ biggest challenges.

SEC original ↗Chemours Co — Earnings release (8-K exhibit)EX-99Aug 5, 2025

The Company does not provide a reconciliation of certain forward-looking non-GAAP financial measures to the most directly comparable GAAP reported financial measures on a forward-looking basis because it is unable to predict with reasonable certainty the ultimate outcome of unusual gains and losses, potential future asset impairments and pending litigation without unreasonable effort.

SEC original ↗Chemours Co — Earnings release (8-K exhibit)EX-99Aug 5, 2025